Ozempic vs Other GLP-1 Medications for Weight Loss: What the Research Actually Shows

When Ozempic became a cultural phenomenon, most people assumed it was the only game in town. It isn’t. The GLP-1 receptor agonist class now includes multiple medications — semaglutide in various forms, tirzepatide, liraglutide, and others — each with meaningfully different efficacy profiles, delivery methods, and clinical evidence behind them. If you’re trying to decide which one belongs in your protocol, or simply trying to understand why your doctor recommended one over another, the research tells a surprisingly detailed story.

Start with the foundation: semaglutide, the active compound in both Ozempic and Wegovy, has arguably the most robust weight loss data of any pharmaceutical outside of bariatric surgery. Across the STEP clinical trial program, semaglutide 2.4 mg produced mean weight losses between 14.9% and 17.4% in adults with overweight or obesity without type 2 diabetes at 68 weeks — with 69% to 79% of participants achieving at least 10% body weight reduction and 51% to 64% hitting the 15% threshold. Those are numbers that, until recently, were associated only with surgical intervention. The key distinction most people miss is that Ozempic is the 0.5 mg to 2 mg dosing of semaglutide approved for type 2 diabetes management — Wegovy is the 2.4 mg version specifically approved for chronic weight management. Same molecule, different ceiling.

Semaglutide Head-to-Head: The STEP Trials and What They Reveal

The STEP trial series is the most comprehensive dataset available for semaglutide’s weight loss potential. STEP 3 combined semaglutide 2.4 mg with intensive behavioral therapy and an initial low-calorie diet, and the results were striking: participants on semaglutide lost an estimated 16.0% of body weight versus 5.7% on placebo at week 68, with 86.6% of the semaglutide group losing at least 5% of baseline weight compared to 47.6% on placebo. Over half the semaglutide group — 55.8% — achieved 15% or more weight loss, against just 13.2% in the placebo group. This matters because it demonstrates that the medication amplifies what lifestyle intervention alone can produce, rather than replacing it.

STEP 4 answered a different but equally important question: what happens when you stop? After a 20-week run-in where participants lost a mean of 10.6% of their body weight on semaglutide, researchers split the group — some continued, some switched to placebo. Those who continued semaglutide lost an additional 7.9% of body weight over the next 48 weeks. Those who stopped regained 6.9%, representing a 14.8 percentage point difference between the two groups. The clinical message is unambiguous: semaglutide works while you take it, and weight returns when you don’t. This isn’t a flaw unique to semaglutide — it reflects the chronic disease model of obesity — but it’s something every man considering GLP-1 therapy needs to understand before starting.

Beyond weight, continued semaglutide also produced meaningful improvements in waist circumference (down 9.7 cm versus placebo), systolic blood pressure (down 3.9 mmHg), and physical functioning scores. For men dealing with metabolic syndrome, hypertension, or visceral adiposity, these secondary outcomes may matter as much as the number on the scale.

Tirzepatide vs Semaglutide: The Dual-Agonist Advantage

Tirzepatide — marketed as Mounjaro for diabetes and Zepbound for obesity — operates differently from semaglutide at a mechanistic level. Where semaglutide exclusively activates the GLP-1 receptor, tirzepatide is a dual agonist that targets both GLP-1 and GIP (glucose-dependent insulinotropic polypeptide) receptors simultaneously. That additional GIP activation appears to meaningfully amplify weight loss outcomes, particularly at higher doses.

A 2024 systematic review and network meta-analysis published in Diabetologia compared subcutaneous tirzepatide and semaglutide across 28 randomized controlled trials involving over 23,000 participants with type 2 diabetes. The findings showed that tirzepatide 15 mg was the most efficacious treatment in reducing both HbA1c and body weight compared to semaglutide at any dose — including the 2.0 mg subcutaneous formulation. This tracks with head-to-head data from the SURMOUNT-5 trial, which found tirzepatide produced roughly 20% body weight reduction in non-diabetic adults with obesity at the highest doses, compared to approximately 14% with semaglutide 2.4 mg. In practical terms, a man who has plateaued on Wegovy may see meaningfully greater results if he transitions to Zepbound — though individual response varies considerably and both medications carry similar GI side effect profiles.

The trade-off with tirzepatide is primarily one of availability and cost. As a newer agent, Zepbound has experienced the same shortage issues that plagued Wegovy in its early years, and prior authorization requirements can make access complicated depending on your insurance situation. Semaglutide, with its longer track record and established supply chain, remains more consistently accessible for most patients.

Oral Semaglutide: A Real Option or a Compromise?

For men who are needle-averse or simply prefer a daily pill over a weekly injection, oral semaglutide — brand name Rybelsus for diabetes, and now the 50 mg formulation under the name Wegovy oral — represents a meaningful development. The OASIS 1 trial, a phase 3 randomized controlled trial published in The Lancet, assessed oral semaglutide 50 mg taken once daily in adults with overweight or obesity without type 2 diabetes. The results were more competitive with injectable semaglutide than many expected: participants lost an estimated 15.1% of body weight at week 68 versus 2.4% with placebo — a treatment difference of 12.7 percentage points. Over a third of the oral semaglutide group achieved 20% or more weight loss.

That said, oral semaglutide comes with adherence requirements that injectable versions don’t. It must be taken fasting, with no more than a small sip of water, at least 30 minutes before any food, drink, or other medication. GI adverse events — predominantly nausea and vomiting — were reported in 80% of oral semaglutide participants versus 46% on placebo, somewhat higher than injectable formulations. For men who can manage those requirements consistently, the oral route delivers results that approximate the injectable standard. For those who travel frequently, eat irregularly, or simply don’t want to think about their medication every morning, the once-weekly injection may be more practical despite the needle.

Liraglutide (Saxenda), the older GLP-1 agent requiring daily injection, generally produces more modest weight loss — typically 5% to 8% at 3 mg — making it less competitive in the current landscape. Most prescribers have moved toward semaglutide or tirzepatide as first-line options when weight loss is the primary goal, and the clinical data supports that shift.

The Takeaway

If you’re evaluating GLP-1 options, the hierarchy of evidence currently looks like this: tirzepatide produces the greatest weight loss at maximal doses, subcutaneous semaglutide 2.4 mg (Wegovy) is the most studied and broadly accessible option, and oral semaglutide 50 mg is a legitimate alternative for those who prefer it. Ozempic — semaglutide at diabetes doses — will produce weight loss, but it’s not optimized for that purpose and generally undershoots what Wegovy delivers. None of these medications work in isolation. The men who see the most durable results are those who use GLP-1 therapy as a tool within a broader framework of resistance training, adequate protein intake, and sustainable dietary habits. The medication changes your appetite signaling. What you do with that change determines how much of it sticks.